Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$13.76 USD
+0.07 (0.51%)
Updated Sep 20, 2024 04:00 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Rigel Pharmaceuticals, Inc. [RIGL]
Reports for Purchase
Showing records 1 - 20 ( 117 total )
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q24 Results; Tavalisse Core Revenue as Rezlidhia and Gavreto Hitting Early Strides; Target Up to $57
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
GAVRETO Set for Imminent U.S. Commercial Launch as Rigel Completes NDA Transfer
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Olutasidenib''s Position Continues to Strengthen with Multiple Presentations at EHA ''24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Olutasidenib''s Profile Building Continues With a Duo of Presentations at ASCO ''24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q24 Results; First Look at Phase 1b R289 Data by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2023 Results; Heme-Onc Asset Revenues Continue to Climb; Commercialization Plan Laid Out For GAVRETO
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
GAVRETO Joins Rigel''s Roster of Marketed Drugs Following Asset Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Continued Pipeline Progress and Commercial Revenue Growth Signal Optimistic Outlook for 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rigel CONNECTs Forces Through New Collaboration in Glioma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Flurry of Encouraging Presentations Across Rezlidhia and Tavalisse at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rigel and MD Anderson Team Up to Broaden REZLIDHIA''s Reach Across Hematologic Cancers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q23 Results; Shares Trading at 1x Projected 2024 Price to Sales Early in Commercial Phases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
COVID-19 Program Updates As Clinical Development Priority Moving Forward Remains On Heme-Onc
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q23 Results; Tavalisse Captures New Patients in Earlier Lines of Therapy; Rezlidhia New Traction Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q23 Results; Tavalisse Continues to Ride the Revenue Wave; Rezlidhia Sales Gain Traction
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2022 Results; Tavalisse Blocking and Tackling; Rezlidhia Impresses Out of the Gate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tavalisse Beats; Rezlidhia Sales Up and Running; Time For New Clinical Developments
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rezlidhia Launches in the U.S. With Confirmed Pricing Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 1b Evaluating R289 in Lower Risk MDS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Christmas Comes Early; Welcome REZLIDHIA to the Sales Bag; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J